Suven gets patents from Australia, Singapore

Suven Life Sciences Ltd. has received a product patent each from Australia and Singapore corresponding to the new chemical entities for the treatment of disorders associated with neuro-degenerative diseases. The patents are valid ill 2036. The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds respectively, developed as therapeutic agents. These include cognitive impairment associated with Alzheimer’s disease, ADHD (attention deficient hyperactivity disorder), Huntington’s disease, Parkinson and Schizophrenia, the company informed the stock exchange on Wednesday.

The company is developing a pipeline of molecules in CNS arena for cognitive disorders that have a high unmet medical need and huge market potential globally, CEO Venkat Jasti said.

Source: Read Full Article